SCHEMBL3650412

SCHEMBL3650412

Clc1ccnc(I)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34470561 1.00
SCHEMBL30386373 0.72
SCHEMBL433889 0.72
SCHEMBL29483856 0.72
SCHEMBL63023 0.72
Fluoride SCHEMBL27460684 0.70
SCHEMBL17621794 0.69
SCHEMBL20461245 0.69
SCHEMBL14390183 0.69
SCHEMBL3366431 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115925684-B Pyrimidine derivative and preparation method and application thereof 徐诺药业(南京)有限公司 2025-02-28 CN claimed
CN-115925684-A Pyrimidine derivative and preparation method and application thereof 徐诺药业(南京)有限公司 2023-04-07 CN claimed
WO-2026090348-A1 THE USE OF SON OF SEVENLESS (SOS) INHIBITOR COMPOUNDS SUCH AS 7-SUBSTITUTED BENZOFURANS TO TREAT CANCER Mirati Therapeutics, Inc. (US) 2026-04-30 WO disclosed
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors ONCODESIGN PRECISION MEDICINE (FR) 2026-02-10 US disclosed
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 US disclosed
EP-4146658-B1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PREC MEDICINE OPM (FR) 2025-10-29 EP disclosed
EP-4554938-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-21 EP disclosed
CN-119894879-A Tyrosine kinase 2 inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-25 CN disclosed
CN-115925684-B Pyrimidine derivative and preparation method and application thereof 徐诺药业(南京)有限公司 2025-02-28 CN disclosed
US-20240217989-A1 Heteroaryl Fluoroalkenes As DGK Inhibitors INCYTE CORPORATION 2024-07-04 US disclosed
WO-2024108100-A1 HETEROARYL FLUOROALKENES AS DGK INHIBITORS INCYTE CORPORATION (US) 2024-05-23 WO disclosed
CN-101754962-A N-azacyclic substituted pyrrole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 for the treatment of diabetes and metabolic disorders METABOLEX INC 2010-06-23 CN disclosed
EP-2185544-A2 N-AZACYCLIC SUBSTITUTED PYRROLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS Metabolex Inc. (US) 2010-05-19 EP disclosed
WO-2010011349-A2 PYRIMIDINE-2,4-DIAMINE JAK2 KINASE INHIBITING ANTI-INFLAMMATION USE SUPERGEN, INC. (US) 2010-01-28 WO disclosed
US-20090137590-A1 N-LINKED HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS METABOLEX INC. 2009-05-28 US disclosed
EP-1654251-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-03-11 EP disclosed
WO-2009014910-A2 N-AZACYCLIC SUBSTITUTED PYRROLE, PYRAZOLE, IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES AS AGONISTS OF THE RUP3 OR GPR119 RECEPTOR FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS METABOLEX, INC. (US) 2009-01-29 WO disclosed
US-20060205740-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2006-09-14 US disclosed
EP-1654251-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-05-10 EP disclosed
WO-2005016914-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-02-24 WO disclosed